UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of September 2022

 

Commission File Number: 001-39997

 

 

 

Adagene Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

4F, Building C14, No. 218

Xinghu Street, Suzhou Industrial Park

Suzhou, Jiangsu Province, 215123

People’s Republic of China

+86-512-8777-3632

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x   Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Adagene Inc.
     
  By: /s/ Peter (Peizhi) Luo
  Name: Peter (Peizhi) Luo
  Title: Chief Executive Officer
     

Date: September 12, 2022

    

 

 

 

EXHIBIT INDEX

 

Exhibit   Description
     
99.1   Press Release titled “Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors”

 

 

 

 

Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Adagene Charts.
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Adagene Charts.